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Background: There are few data describing the microbiology and genetic typing of Staphylococcus aureus that
cause infections in developing countries.
Methods: In this study we observed S. aureus infections in Pacific Island nation of Fiji in both the community and
hospital setting with an emphasis on clonal complex (CC) genotyping and antimicrobial susceptibility.
Results: S. aureus was commonly found in impetigo lesions of school children and was recovered from 57% of
impetigo lesions frequently in conjunction with group A streptococcal infection. Methicillin-resistant S. aureus
(MRSA) comprised 7% (20/299) of isolates and were all non-multi-resistant and all genotyped as CC1. In contrast,
there was a diverse selection of 17 CCs among the 105 genotyped methicillin-susceptible S.aureus (MSSA) strains.
Isolates of the rare, phylogenetically divergent and non-pigmented CC75 lineage (also called S.argenteus) were
found in Fiji.
From hospitalized patients the available 36 MRSA isolates from a 9-month period were represented by five CCs.
The most common CCs were CC1 and CC239. CC1 is likely to be a community-acquired strain, reflecting what was
found in the school children, whereas the CC239 is the very successful multi-drug resistant MRSA nosocomial lineage.
Of 17 MSSA isolates, 59% carried genes for Panton-Valentine leukocidin. The S. aureus bacteraemia incidence rate of
50 per 100,000 population is among the highest reported in the literature and likely reflects the high overall burden of
staphylococcal infections in this population.
Conclusions: S. aureus is an important cause of disease in Fiji and there is considerable genotypic diversity in
community skin infections in Fijian schoolchildren. Community acquired- (CA)- MRSA is present at a relatively low
prevalence (6.7%) and was solely to CC1 (CA-MRSA). The globally successful CC239 is also a significant pathogen in Fiji.
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Staphylococcus aureus is one of the most successful
human pathogens. The dispersion of certain successful
lineages can be tracked across the globe [1]. Since first
being recognised in the early 1960s, methicillin-resistant
S. aureus (MRSA) emerged as an important worldwide
pathogen associated with nosocomial infections in the
developed world, so-called healthcare-associated MRSA
(HA-MRSA) [2]. In the last two decades however,* Correspondence: jenneya@unimelb.edu.au
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reproduction in any medium, provided the orcommunity-associated MRSA (CA-MRSA) strains have
been observed to cause disease in people without health-
care contact. At-risk groups have been identified, includ-
ing sports teams, prisoners, military personnel, and
Indigenous population groups. In addition, S. aureus
lineages have demonstrated a degree of geographical
restriction [3].
While extensive data on the burden of disease due to
S. aureus are available from many industrialised coun-
tries, there are few data from developing countries. In an
analysis of 220 papers concerning hospital-acquired in-
fection in developing countries, S. aureus was the second
most recognised cause after the Enterobacteriaceae; anti-
biotic resistance was recorded in just eight of the studiesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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were found to be methicillin resistant [4]. In a study of
S. aureus from rural Thailand, S.aureus caused similar
clinical manifestations of disease as those seen in more
developed countries but an increased mortality was
noted [5]. Within developed countries, S. aureus has
been found to cause significant disease amongst certain
disadvantaged populations, including Indigenous com-
munities [6]. For example, in a study of impetigo in an
urbanised population of Indigenous Australians in Far
North Queensland in Australia, S. aureus was isolated
from 92 of 118 cases (78%) of which 16% were CA-
MRSA [7]. In a study of impetigo in remote Aboriginal
communities in northern Australia, S. aureus was isolated
in 59% of impetigo lesions and 23% were CA-MRSA [8].
Furthermore, in northern Australia, the incidence of S.
aureus bacteraemia in the Indigenous population was 5.8
times that of non-Indigenous Australians [9].
Infection due to S. aureus is thought to be the cause of
significant disease in Pacific Island Countries (PICs) [10].
There is a large burden of impetigo due to S. aureus and
Streptococcus pyogenes in many PICs, often due to second-
ary infection of scabies [11]. Although there are few
population-based studies of S. aureus in the Pacific region,
CA-MRSA is known to occur in the region. One particu-
lar strain of S. aureus, the so-called South-West Pacific
(SWP) CA-MRSA clone, has been prevalent in in Samoan
patients living in New Zealand, and also Pacific Island
people populations in Australia [12]. Outbreaks of CA-
MRSA have also been described in Pacific Island people
populations in Hawaii [13], and amongst Samoans living
in Alaska [14] and in Samoa itself [15].
Given the paucity of data regarding the clinical micro-
biological features as well as the molecular epidemiology
of S. aureus from the Pacific Islands, the aim of this
study was to describe the clinical and microbiologic epi-
demiology of infections amongst school children and
hospital inpatients with S. aureus in the Republic of Fiji.
Other aims included an examination of the incidence of
S.aureus bacteraemia amongst different populations of
Fijian residents. The study also sought to describe the
frequency of MRSA infections among those with impe-
tigo in schools to determine if a change was required
from the current practice of using empiric beta lactam
antibiotics for suspected S.aureus infections.
Methods
Setting
Fiji has a population of approximately 837,000 people
living in some of its 330 islands in the tropical Western
Pacific. The majority of the population is i-Taukei
(Indigenous Fijian) with a large minority (37%) being
Fijians of Indian descent [16]. We conducted two separate
studies: the first was a prospective cohort survey ofimpetigo in 450 children over a period of 10 months in 3
primary schools in Fiji [11], and the second was a retro-
spective study of S. aureus isolated from clinical specimens
sent to the microbiology laboratory at the Colonial War
Memorial Hospital (CWMH) in the capital city of Suva.
Community study
This was a prospective cohort study to investigate the
part played by S. aureus in the causation of impetigo in
school children aged 5 – 15 years in three schools con-
ducted in 2006 [11]. Two of these were schools located
in a rural area where the population was predominantly
iTaukei, whilst the third (and largest) school was located
in Suva with a population predominantly of Fijians of
Indian descent. Each school was visited six times over a
ten-month period at two monthly intervals and at each
visit the children were examined for impetigo. Infected
skin lesions were swabbed and swabs were placed in air-
tight bags with desiccant for transportation back to the
laboratory in Suva. The swabs were plated onto sheep
blood agar and incubated at 37°C for 24–48 hours [5].
S. aureus was identified by colony morphology and a
latex slide agglutination test [Staphaurex Remel, Lenexa,
KS, USA]. Isolates were stored in glycerol and transferred
frozen to Darwin, Australia for further testing (described
below).
Hospital study
In this study isolates were collected from the diagnostic
microbiology laboratory of the CWMH, Suva, the coun-
try’s largest hospital serving the Central Division of Fiji,
which is inhabited by approximately one third of the na-
tion’s population. Over a nine-month period September
2006 to May 2007, consecutive isolates of MRSA were
collected from sterile and non-sterile sites and where
possible, clinical and demographic data were collected
from the patients’ medical record. During this time a
small proportion (approximately 5% of the total identi-
fied in the laboratory) of MSSA isolates were collected
(each MSSA isolate selected was identified temporally as
close as possible to each MRSA isolate collected). This
was done to ascertain some molecular epidemiological
data of the MSSA isolates causing symptoms at the
same time as the MRSA isolates that were being inves-
tigated. This yielded a similar number of MSSA as
MRSA isolates, over the same time period. [From the
four annual surveys, prior to this study, conducted by
the scientist at the CWMH laboratory, approximately
85% of the S.aureus isolates came from swabs and 3-5%
were MRSA (S. Pravin, personal communication)]. Also
during this time the blood culture isolates of S.aureus
were enumerated to calculate the incidence of S.aureus
bacteraemia. We used the population of the Central
Division of Fiji from the 2007 national census as the
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occurred during 2006 (4 months) and 2007 (5 months),
we extrapolated a total population figure for 2006 using
the pro rata difference between the last official census in
1996 and the latest census in 2007. In calculating average
annualized rates, the denominator of person-months was
calculated by multiplying each year’s population by the
number of months of surveillance for each year (i.e. 2006
population by 4 months and 2007 population by 5 months)
and adding these totals. The total number of cases over
the 9 months was then divided by the total person-
months and multiplied by 12 to give average annualized
incidence rates with binomial exact 95% confidence inter-
vals (CI). Incidence rate ratios were used to compare rates
between ethnic groups.
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was undertaken using
the Vitek2 automated system [BioMerieux, Mary l’etoile,
France] as per the manufacturer’s instructions. We consid-
ered non–multidrug-resistant MRSA (nmMRSA) isolates
to represent CA-MRSA strains and considered multidrug-
resistant MRSA (mMRSA) isolates to represent HA-MRSA
strains [17]. nmMRSA isolates were defined phenotypically
as those isolates resistant to beta-lactam antibiotics but re-
sistant to no more than one other class of antibiotic, and
mMRSA isolates were defined as those resistant to two or
more classes of antibiotic in addition beta-lactam antibi-
otics. Antibiotic phenotype has previously been shown to
accurately predict the genotype of CA-MRSA strains [18],
and this result has been validated in various studies from
Australia [6,9,17,19,20].
Molecular typing
Using real-time polymerase chain reaction (PCR), S. aureus
was verified by confirming the presence of nucA gene,
MRSA was confirmed by the presence of mecA gene. The
presence Panton Valentine leukocidin (PVL) has been as-
sociated with particularly virulent disease in some studies
of CA-MRSA particularly. The ability to produce PVL was
detected by the presence of lukS-PV-lukF-PV genes [21]. A
proportion of the collected isolates were genotyped by
means of a single-nucleotide polymorphism (SNP) geno-
typing system based on the multilocus sequence type
(MLST) database, as previously elsewhere [8,21]. Of the
303 isolates 105 were selected for typing. These isolates
came from throughout the whole collection period, and
though not randomly chosen, there was no regard to indi-
vidual isolate selection thereby avoiding bias as much as
possible. In short, a kinetic PCR method was used to inter-
rogate 8 highly discriminatory SNPs, allowing isolates to be
assigned into eBURST [22] derived clonal complexes
(CCs). Sequencing of selected MLST loci of some isolates
was carried out using standard MLST primers andmethodology for S. aureus [23]. Investigation of spa type
diversity was performed using a high-resolution melting
(HRM) assay of the spa locus [24].
Statistical analysis
Data were analysed using non-parametric formulae in Stata
version 9.1 (Stata-Corp, College Station, Texas, USA). The
population-based incidence of S. aureus bacteraemia was
calculated using the census data for the Central Division of
Fiji as the denominator.
Ethical approval
Ethical approval for this study was obtained from the Fiji
National Research Ethics Review Committee, the Fiji
National Health Research Committee and the Human
Research Ethics Committee at the University of Melbourne.
Children were only enrolled if written consent from a par-
ent or guardian was obtained, and in the case of children
aged ten years or older, if written assent was also obtained.
Results
Community study
A total of 563 swabs were taken from 455 children (108
children had two swabs taken at the same visit from two
infected sites) and there was bacterial growth from 522
swabs (92.7%). There was growth of beta-haemolytic strepto-
cocci (predominantly Streptococcus pyogenes) from 491 swabs
(87.2%), and S. aureus was isolated from 323 swabs
(57.4%), co-existing with beta-haemolytic streptococci
in 292 swabs (51.9%).
Antimicrobial resistance testing was performed on 299
of the 323 isolates. 20 isolates (6.7%, 95% CI 4.1 – 10.1)
from 14 children were found to be nmMRSA, 17 under-
went SNP-typing, and all were CC1 and PVL negative.
Of the remaining 303 MSSA isolates, 105 underwent
SNP-typing. There was a wide distribution of CCs among
the MSSA isolates (Figure 1) with the most common be-
ing CC5, 7, 14, 75 and 121. As the CC75 lineage has been
noted to be non-pigmented in collections from northern
Australia, we also demonstrated that all CC75 strains from
this study were also non-pigmented when grown in LB
broth. This CC75 lineage has provisionally been named S.
argenteus given its divergent phylogenetic position [25]
and non-pigmented phenotype and will herein be referred
to as S. argenteus. Two isolates produced a previously
undescribed SNP profile and full MLST revealed that they
were a new MLST sequence type, which is a single locus
variant of ST96. PVL positive strains comprised 26 of the
105 isolates and were all of the CC30 (7), CC119 (1) and
CC121 (12) isolates and 6 of the 20 CC7 isolates.
Hospital setting
Of the 36 MRSA isolates that underwent antimicrobial
susceptibility testing and genotyping, 14 (39%) were
i i
Figure 1 Clonal complex types of S.aureus isolated from Fijian
schoolchildren’s impetigo lesions. Clonal complexes identified
from SNP-typing of Staphylococcus aureus isolates collected from
impetigo lesions in school children in Fiji (MSSA: methicillin sensitive
Staphylococcus aureus; nmMRSA: non–multidrug-resistant methicillin
resistant Staphylococcus aureus; PVL: Panton Valentine Leukocidin).
Jenney et al. BMC Infectious Diseases 2014, 14:160 Page 4 of 7
http://www.biomedcentral.com/1471-2334/14/160mMRSA and all of these were of the globally recog-
nised HA-MRSA lineage (ST239) and were PVL nega-
tive. The other 22 MRSA isolates were of the nmMRSA
susceptibility phenotype, of which 5 (23%) were PVL
positive (all were CC30). Of the remainder, fifteen were
CC1, one was CC59 and one was CC101 (Figure 2).
Of the 27 MSSA isolates analysed, there were nine
different CCs, and 59% (16/27) of isolates were PVL
positive. To determine if a particular sub-lineage of theFigure 2 Clonal complex types of S.aureus isolated from
patients at CWMH, Fiji. Clonal complexes identified from SNP
typing of Staphylococcus aureus isolates collected from the
Colonial War Memorial Hospital, Fiji (MSSA: methicillin sensitive
Staphylococcus aureus; nmMRSA: non–multidrug-resistant
methicillin resistant Staphylococcus aureus; mMRSA: multidrug-resistant
MRSA; PVL: Panton Valentine Leukocidin).community-based CC1 strains was causing hospital in-
fections we investigated diversity at the spa locus with
HRM. We found that 3 HRM curves were present in
similar proportions in both community and hospital
isolates (community strains: HRM spa 1 (2 isolates),
HRM spa 2 (14), HRM spa 3 (3); hospital strains: HRM
spa 1 (1), HRM spa 2 (14), HRM spa 3 (3), non-
typeable (2)).
Clinical features of patients with MRSA infection
Clinical information was available for 22 patients that
had MRSA isolates. Eight of these 22 isolates were from
infected surgical wounds, seven from non-surgical skin
infections, two from CSF and one from blood culture.
The median age was 43.5 years (range, 2 months–
77 years); 55% were female; 16 were iTaukei, three were
Fijians of Indian descent and 3 were ‘other’ ethnicity.
Eight had had a history of hospitalisation or surgical
procedures in the 12 months prior to the isolate being
identified and 15 (68%) had received antibiotics (from
CWMH) in the previous year. Eleven had diabetes melli-
tus and of these, five had MRSA isolated from diabetic
foot infections. The median length of hospitalisation was
22 days (interquartile range, 15 to 36 days).
Incidence of S aureus bacteraemia
There were 128 separate episodes of S. aureus bacter-
aemia over the 9-month study period. This equated to
an all-ages incidence figure for the Central Division of
Fiji of S. aureus bacteraemia of 50.1 cases per 100,000
population (95% confidence interval, CI, 41.8 – 59.5)
with peaks in children aged less than 5 years and adults
aged 55 to 64 years (Figure 3). The incidence was high-
est in iTaukei (all-ages incidence 66.2 per 100,000, 95%
CI 54.2 – 80.1), and iTaukei were three times as likely to
have S. aureus bacteraemia compared with people of
other ethnic backgrounds (incidence rate ratio 3.0, 95%
CI 1.9 – 5.1). Only 3 of the 128 isolates were MRSA
(2.3%). No further clinical information was available.
Discussion
Although this study found a relatively low incidence of
MRSA in Fiji in the community setting, the overall inci-
dence of S. aureus bacteraemia was very high. There was
considerable diversity of CC types seen amongst the
CA-MRSA and the MSSA isolates, and this diversity was
seen in both the community and hospital settings. While
CC1 was the most common lineage observed and found
both in the community and hospital studies, the CC239
clone was found to be well-established amongst hospital
patients similar to more developed nations.
CC1 has also been found to represent 26% of MRSA
strains in the Pacific Island nation of Samoa [15]. Further
sub-typing of CC1 strains demonstrated that there was no
Figure 3 Annualised incidence of S.aureus bacteraemia at CWMH, Fiji. Number of cases and annualised incidence of cases where
Staphylococcus aureus was cultured from blood at the Colonial War Memorial Hospital, Central Division, Fiji, May 2006 – September 2007 showing
a predominance of cases amongst the iTaukei (Indigenous Fijian) population.
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sub-lineage as a cause of hospital infections. CC239 is the
typical HA-MRSA lineage found in Australia and Asia
[26], and is evidently present in Fiji as a cause of nosoco-
mial infections. With regards to CC30 MRSA, although
the name SWP lineage would suggest an origin from this
region of the world, it only comprised five of the 22
nmMRSA of hospital isolates and is most likely not a
dominant lineage in either Fiji or Samoa [15].
Perhaps most surprising was the presence of S. argenteus
strains. This divergent and early-branching lineage of
S. aureus is prevalent in Indigenous populations in
northern Australia, [8,27] and in an Amazonian tribe
in French Guinea [28]. S. argenteus typically lacks the
genes for production of the carotenoid pigment sta-
phyloxanthin [25] and is hypothesised to be well
adapted to causing skin infections and to be less viru-
lent than other S. aureus lineages [29]. Findings from
our current study extend the geographical distribution
of this unusual lineage and confirm its non-pigmented
phenotype. In addition, we provide supportive evidence
regarding its virulence and epidemiological niche in that it
represented 8.2% of community based impetigo isolates
but only 1.6% of hospital based clinical isolates.
Our study found a prevalence of CA-MRSA in impe-
tigo lesions among Fiji children of 6.7%, which is similar
to a reported prevalence of 9% in Samoa [15]. This is in
striking contrast to reports of high prevalence of CA-
MRSA among Pacific Island peoples and Australian
Aboriginal populations living in developed country set-
tings [9,30,31]. The reason for the lower prevalence in
Fiji is unclear, particularly as many of the conditions
thought to contribute to the emergence of CA-MRSA in
Indigenous populations in the developed world setting
[6] are also present in Fiji. These factors are likely to in-
clude overcrowding, inadequate health-hardware for
washing of clothes and people, poor skin hygiene andhigh rates of antibiotic use and further research specific
to Fiji to investigate these is required. The prevalence of
MRSA among hospital isolates of S. aureus in Fiji is also
low; in the year prior to this study the proportion of all
S.aureus isolates from the CWMH laboratory that were
methicillin-resistant was 5% (personal communication,
S. Pravin).
The incidence of SAB of 50.1 per 100,000 overall and
66.2 per 100,000 for the i-Taukei (Indigenous Fijian)
population is considerably higher than that reported
from developed countries [32] and is similar to that seen
in Indigenous populations in both northern Australia
(65 per 100,000) [9] and for the whole of Australia (62.5
per 100,000) [33]. The age distribution is also similar to
that in Indigenous Australian populations with a peak
incidence in the 45–65 age group. This is in stark con-
trast to that seen in developed countries, including the
non-Indigenous population of Australia, where incidence
increases with age [32,33]. Although we cannot infer a
causative link, there is likely to be an association be-
tween high rates of skin and soft tissue infections and
the high incidence of SAB in both Fiji and Indigenous
Australian populations. Community-based efforts to im-
prove skin health among these populations [34,35] will
hopefully result in reduced rates of skin and soft tissue in-
fections, and it will be important to determine if there is a
concurrent reduction in incidence rates of community-
onset SAB.
The hospital study identified consecutive patients that
had MRSA isolated from clinical specimens sent to the
hospital laboratory for culture, and in this small sample
MRSA was primarily isolated from wounds (post-surgical
or community acquired injuries). From the molecular typ-
ing data it appears that CC239 is commonly observed in
hospital in Fiji and given the experience worldwide it
would be expected that this is a nosocomial isolate. The
nmMRSA CC1 isolates that were identified in the hospital
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nity prior to admission, as the only MRSA detected in
community study (in children that had likely not been
to hospital) was CC1. However, these data come from a
very brief snapshot of S. aureus infections at CWMH. It
has been noted elsewhere that CA-MRSA isolates most
frequently associated with community-associated infec-
tions can become established as the aetiology of noso-
comial infections, [36] and therefore we cannot rule
out this phenomenon occurring at CWMH.
Notably, of the hospital-based MSSA isolates, 59% car-
ried pvl genes. While this represented only 16 of 27 iso-
lates it is both surprising and concerning but is similar
to findings in Africa [37] and Indigenous populations in
northern Australia [29] where PVL was present in 57%
and 40% of MSSA isolates respectively. Although we did
not collect clinical information on the infections caused
by these isolates, it nonetheless suggests that there is a
large burden of PVL + MSSA disease given that MSSA
represents >95% of S. aureus isolates at CWMH.
There are a number of limitations to our study. The
community portion of our study investigated one type of
clinical infection (impetigo) in one demographic group
(school children) in two closely related regions of Fiji. A
broader investigation of staphylococcal infections that
includes older members of the community and a wider
geographic region would be valuable. Within this school
group there may also be may be an under-estimation of
staphylococcal disease in this population as the surveys
took place at two-monthly intervals it is likely that some
episodes of impetigo occurred between visits and there-
fore were missed. The hospital portion of our study had
a narrow time frame and a small numbers of cases
(especially those where clinical information was avail-
able) and so the conclusions from this part of the study
are limited.
Conclusions
Despite these limitations it is clear that S. aureus is an im-
portant cause of disease in Fiji and there is considerable
genotypic diversity in community skin infections in Fijian
schoolchildren. CA- MRSA is present at a relatively low
prevalence (6.7%) and in this survey was found to be due
solely to CC1 (CA-MRSA). Isolates typically associated
with both CA-MRSA and HA-MRSA isolates were found
in the hospital setting with CC239 responsible for all of the
HA-MRSA in this series. Beta-lactam agents, such as clox-
acillin, remain the first choice for community-acquired S.
aureus infections in Fiji. However, if the initial clinical re-
sponse is poor then appropriate therapy for MRSA should
be considered, such as clindamycin or vancomycin.
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